Astrazeneca (AZN) Invested Capital (2009 - 2025)

Astrazeneca's Invested Capital history runs 14 years deep, the most recent figure standing at $78.3 billion for Q4 2025.

• In Q4 2025, Invested Capital rose 10.08% year-over-year to $78.3 billion; the TTM figure through Dec 2025 stood at $78.3 billion (up 10.08% YoY), while the FY2025 annual figure was $78.3 billion, up 10.08% from the prior year.
• Invested Capital was $78.3 billion for Q4 2025 at Astrazeneca, up from $71.2 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $78.3 billion in Q4 2025 to a low of $15.7 billion in Q2 2021.
• Historically, Invested Capital has averaged $53.6 billion across 5 years, with a median of $66.3 billion in 2022.
• The sharpest annual moves came in 2021 and 2022: Invested Capital jumped 3928.45% in 2021, then declined 5.39% in 2022.
• A 5-year view of Invested Capital shows it stood at $70.1 billion in 2021, then retreated by 5.39% to $66.3 billion in 2022, then increased by 2.26% to $67.8 billion in 2023, then climbed by 4.98% to $71.2 billion in 2024, then advanced by 10.08% to $78.3 billion in 2025.
• The last three Invested Capital figures came in at $78.3 billion (Q4 2025), $71.2 billion (Q4 2024), and $39.5 billion (Q2 2024), per Business Quant data.